Damora Therapeutics Inc. Company Profile
NASDAQ: DMRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Damora Therapeutics at a glance
Damora Therapeutics Inc. (NASDAQ: DMRA) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Waltham, MA, Denmark. Damora Therapeutics is led by Ms. Jennifer A. Jarrett M.B.A. and employs about 7 people. The company's shares have traded publicly since 2020.
At a market capitalization of $1.25 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001800315, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Damora Therapeutics do?
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Damora Therapeutics Inc.
- Ticker
- NASDAQ: DMRA
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Jennifer A. Jarrett M.B.A.
- Employees
- 7
- Headquarters
- Building 23, Waltham, MA, Denmark
- Phone
- 781 281 9020
- Website
- damoratx.com
- IPO year
- 2020
- Market cap
- $1.25B
- SEC CIK
- 0001800315
- Latest annual report
- 10-K · Mar 19, 2026
Companies similar to Damora Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ORICOric Pharmaceuticals Inc. | 12.03 | +0.17% | $1.25B | vs DMRA |
| KLRAKailera Therapeutics Inc. | 10.00 | -5.03% | $1.30B | vs DMRA |
| KARDKardigan Inc. | 14.20 | +2.68% | $1.33B | vs DMRA |
| NBTXNanobiotix S.A. ADR | 22.90 | -6.99% | $1.17B | vs DMRA |
| HROWHarrow Inc. | 30.52 | -0.33% | $1.14B | vs DMRA |
| TRAXFirst Tracks Biotherapeutics Inc. | 32.01 | +4.64% | $1.14B | vs DMRA |
| AVLNAvalyn Pharma Inc. | 25.72 | +0.74% | $1.14B | vs DMRA |
| AAPGAscentage Pharma Group International American Depository Shares | 14.55 | -4.09% | $1.36B | vs DMRA |